1.57
+0.0526(+3.46%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.54 |
| Day High | 1.62 |
| Day Low | 1.52 |
| 52-Week High | 75 |
| 52-Week Low | 1.46 |
| Volume | 84,201 |
| Average Volume | 163,659 |
| Market Cap | 2.92M |
| PE | -0.13 |
| EPS | -12.12 |
| Moving Average 50 Days | 6.99 |
| Moving Average 200 Days | 14.49 |
| Change | 0.05 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $1.57 as of August 22, 2025 at a share price of $1.573. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $5.64 as of August 22, 2025 at a share price of $1.573.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
GlobeNewswire Inc.
Aug 13, 2025 8:05 PM GMT
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stag
BioVie Inc. Announces Closing of $12 Million Public Offering
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and
BioVie Inc. Announces Pricing of $12 Million Public Offering
GlobeNewswire Inc.
Aug 08, 2025 12:43 AM GMT
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and